Salbutamol significantly increases cerebral perfusion in proof-of-concept trial
In the Phase I trial, the beta-2 adrenoceptor agonist salbutamol significantly increased cerebral perfusion, a key biomarker in neurodegenerative disease.
List view / Grid view
In the Phase I trial, the beta-2 adrenoceptor agonist salbutamol significantly increased cerebral perfusion, a key biomarker in neurodegenerative disease.
In a Phase III trial, Proxalutamide reduced mortality and expedited recovery of hospitalised COVID-19 patients in Brazil.
In a high-risk patient cohort, treatment with the combination of bamlanivimab and etesevimab reduces COVID-19 related hospitalisation and death by 87 percent.
The highest doses of the novel maturation inhibitor, GSK3640254, had the greatest antiviral activity and were shown to be safe in 34 treatment-naïve adults with HIV.
ASC40 reduced liver fat and significantly lowered an enzyme associated with liver inflammation in nonalcoholic steatohepatitis (NASH) patients.
Zolgensma, a one-off, potentially curative treatment for type 1 spinal muscular atrophy, is set to become the most expensive drug ever approved for use on the UK’s NHS.
European Pharmaceutical Review reports on some of the latest developments in treatments for type 2 diabetes and obesity.
Phase II data suggests intravenous QUZYTTIR™ cetirizine hydrochloride can decrease infusion reactions to anti-CD20 antibody treatments and reduce time to discharge after therapy.
The human medicines committee decided that there was significant evidence to endorse the use of a combination of bamlanivimab and etesevimab in outpatients at high risk of severe COVID-19.
In a trial of over 400 adult patients with mild COVID-19, ivermectin did not significantly improve the time to symptom resolution compared to placebo.
The novel microneedle array uses electroosmotic flow and a series of interconnected micropores to deliver large molecules or extract of fluid samples.
The sub-studies evaluating VIR-7831 and BRII-196 with BRII-198 have stopped enrolment based on recommendations from the Data and Safety Monitoring Board.
Under a licensing and collaboration agreement, Partner Therapeutics will evaluate whether FX-06 could be used to treat multiple biothreats of interest to the US Government.
The trial evaluating COVID-19 convalescent plasma as a treatment for COVID-19 patients with mild to moderate symptoms was stopped due to ineffectiveness.
FOR-6219 was found to be safe and well tolerated by healthy pre- and postmenopausal women and did not induce systemic oestrogen deficiency-related side effects.